The groundwork for the lipid nanoparticle delivery systems used in mRNA COVID-19 vaccines was laid more than 40 years ago in the lab of Dr. Pieter Cullis at the University of British Columbia. He has played a founding role in a number of companies developing pharmaceutical solutions based on drug delivery research, including Inex Pharmaceuticals, Acuitas Therapeutics, and Precision Nanosystems. The success of theses vaccines is the tip of the iceberg for genetic medicine.
Cross-sectoral co-leaders organizations:
- Precision Nanosystems
- Inex Pharmaceuticals
- Acuitas Therapeutics
UBC faculty co-leader:
- Dr. Pieter Cullis (Biochemistry)